Ivabradina Cinfa

Active Ingredient:: Ivabradine Hydrochloride
Origin:: EU

Ivabradina Cinfa (Ivabradine Hydrochloride)

Q: What is Ivabradina Cinfa used for?

Ivabradina Cinfa contains ivabradine, which is used to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction, helping to relieve chest pain and improve cardiac efficiency.

Q: How does ivabradine work?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. This inhibition slows spontaneous depolarisation, reducing resting heart rate without decreasing the strength of cardiac contraction.

Q: What is the usual dose of Ivabradina Cinfa?

The appropriate dose is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. Dosage adjustments are made according to therapeutic goals and safety monitoring.

Q: Is Ivabradina Cinfa safe in pregnancy or breastfeeding?

Safety data for ivabradine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Q: How do I order Ivabradina Cinfa from GNH India?

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but beta‑blockers also reduce myocardial contractility and blood pressure. Ivabradine specifically targets the If current, offering heart‑rate reduction without affecting contractile force, which can be advantageous when beta‑blocker tolerance is limited.

Q: How should Ivabradina Cinfa be stored and handled?

Store the tablets below 25 °C in the original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Q: How is Ivabradina Cinfa administered?

The medication is taken orally, usually with a glass of water. It should be swallowed whole and not crushed or chewed. Dosing times are typically spaced evenly, often twice daily, as directed by the prescriber.

Q: What are the most serious risks associated with Ivabradina Cinfa?

The most serious adverse events include severe bradycardia (heart rate <50 bpm), atrial fibrillation, and persistent visual disturbances that may indicate retinal toxicity. Prompt medical evaluation is required if any of these symptoms occur.

Q: Who should not use Ivabradina Cinfa?

Ivabradina Cinfa is contraindicated in patients with sick sinus syndrome, severe hepatic impairment, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Ivabradina Cinfa, is an If channel inhibitor presented as an oral tablet for oral use. It is employed to lower heart rate in patients with chronic stable angina pectoris and in those with heart failure with reduced ejection fraction.

GNH India supplies Ivabradina Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory documentation for global distribution, including batch release certificates and stability data.

Manufacturer / TM Owner

Laboratorios Cinfa S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where heart‑rate control improves outcomes.

Chronic stable angina pectoris: reduces myocardial oxygen demand by lowering heart rate, relieving anginal symptoms.
Heart failure with reduced ejection fraction: improves left‑ventricular function and lowers hospitalization risk by controlling heart rate.
Exercise‑induced angina: facilitates better exercise tolerance by preventing excessive heart‑rate rise.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which modulates spontaneous depolarisation. By blocking this inward sodium/potassium mixed current, the drug slows the pacemaker activity without affecting myocardial contractility, resulting in a reduced resting heart rate while preserving ventricular performance.

Side Effects

Common Side Effects

Bradycardia: slowed heart rate that may cause fatigue.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache: mild to moderate pain.
Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

Severe bradycardia: symptomatic heart‑rate <50 bpm requiring medical attention.
Atrial fibrillation: irregular rhythm that may need treatment.
Allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

When prescribing Ivabradina Cinfa, clinicians should consider the following precautions:

Heart‑rate monitoring: check resting heart rate before initiation and periodically thereafter.
Contraindication in sick sinus syndrome: avoid use in patients with intrinsic sinus node dysfunction.
Severe hepatic impairment: use with caution or avoid.
Concurrent strong CYP3A4 inhibitors: avoid co‑administration.
Pregnancy and lactation: safety not established; weigh risks and benefits.

Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradina Cinfa may interact with several drug classes.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure.
Other bradycardic agents (e.g., beta‑blockers, digoxin): combined use can cause excessive heart‑rate reduction.
Concomitant use with other If channel inhibitors: avoid.

Moderate Interactions (Monitor Closely)

Calcium‑channel blockers (verapamil, diltiazem): may modestly raise ivabradine levels.
CYP3A4 inducers (rifampicin, carbamazepine): may reduce efficacy.
Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure.

Frequently Asked Questions

Ivabradina Cinfa contains ivabradine, which is used to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction, helping to relieve chest pain and improve cardiac efficiency.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. This inhibition slows spontaneous depolarisation, reducing resting heart rate without decreasing the strength of cardiac contraction.

The appropriate dose is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. Dosage adjustments are made according to therapeutic goals and safety monitoring.

Safety data for ivabradine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but beta‑blockers also reduce myocardial contractility and blood pressure. Ivabradine specifically targets the If current, offering heart‑rate reduction without affecting contractile force, which can be advantageous when beta‑blocker tolerance is limited.

Store the tablets below 25 °C in the original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date printed on the packaging.

The medication is taken orally, usually with a glass of water. It should be swallowed whole and not crushed or chewed. Dosing times are typically spaced evenly, often twice daily, as directed by the prescriber.

The most serious adverse events include severe bradycardia (heart rate <50 bpm), atrial fibrillation, and persistent visual disturbances that may indicate retinal toxicity. Prompt medical evaluation is required if any of these symptoms occur.

Ivabradina Cinfa is contraindicated in patients with sick sinus syndrome, severe hepatic impairment, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.